Merck logo

Merck

Last updated January 31, 2026
124
Innovation Areas
5,362
Inventors
47
Collaborations

Automated biocontainer sampling interface: MerckRecent Research Landscape

Unsynchronized automation tasks create audit gaps and operational latency in particle monitoring. This architecture enforces verifiable execution sequences to ensure regulatory compliance and data integrity.

What technical problems is Merck addressing in Automated biocontainer sampling interface?

Biological sample integrity loss

(14)evidences

Contamination risks and lack of verifiable chain of custody during the collection of volatile or particulate samples. Ensuring data provenance and physical sample purity prevents false positives in sensitive biocontainment monitoring.

Bioprocess fluid contamination risks

(14)evidences

Human intervention during fluid extraction introduces microbial or particulate impurities. Eliminating manual handling ensures sterile integrity and process repeatability.

Bioprocess monitoring latency

(13)evidences

Inaccurate measurement readings caused by environmental interference or probe degradation in single-use systems. Eliminating signal error ensures precise control of critical process parameters without manual recalibration.